[A20-69] Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V

Last updated 04.02.2021

Project no.:
A20-69

Commission:
Commission awarded on 07.08.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Airways and respiratory system

Indication:

Adults with asthma not adequately controlled with a maintenance combination of a LABA and a high dose of an ICS who experienced one or more asthma exacerbations in the previous year

Result of dossier assessment:

No statistically significant differences in any outcome; added benefit not proven

Federal Joint Committee (G-BA)

2021-02-04: A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form